Thymogen

What is Thymogen?

Thymogen is a synthetic dipeptide made of two amino acids, glutamic acid and tryptophan, written as Glu-Trp or EW. It was developed in the Soviet Union by the group led by Vladimir Morozov and Vladimir Khavinson, who identified it as an active component of Thymalin, their calf thymus extract. It is registered in Russia as an immunostimulant and its international nonproprietary name is oglufanide.

Thymogen belongs to the family of short peptide bioregulators associated with Khavinson's institute in St. Petersburg. Each of these di- to tetrapeptides is claimed to act on a specific tissue. Thymogen is the one aimed at the thymus and immune system.

It is one of a group of immune drugs that were widely used in the former Soviet bloc but remain almost unknown in Western medicine. A review of such drugs lists Thymogen among the immunomodulators thought to work partly by inducing interferon.¹ In the US, it is sold online as a research peptide for immune support and recovery from infection.

One important caution: nearly all supporting research comes from a single research network in Russia and has not been independently replicated under current trial standards. That limitation applies to the whole bioregulator class.

How Thymogen works

The thymus trains immature immune cells to become T cells. When the immune system is weakened by illness, injury, stress or age, T-cell numbers and function can fall. Thymogen is meant to act as a small signal that helps restore normal T-cell development and activity, without strongly stimulating an immune system that is already working normally.

Its developers propose that short peptides such as Thymogen enter cells and interact directly with DNA to switch tissue-specific genes on or off. This idea is central to the bioregulator theory, but it has not been confirmed by independent laboratories and is not an accepted mechanism in mainstream pharmacology.

In more precise terms, Thymogen is L-glutamyl-L-tryptophan. A 2024 review describes it alongside Thymodepressin, a drug built from the mirror-image D-forms of the same two amino acids, which acts as an immune suppressant instead. The authors present this pair as the first example of mirror-image peptide drugs with opposite effects on immune balance.² Russian reviews of thymus and pineal aging also include Thymogen among the thymic peptides studied for effects on age-related involution.³ The specific receptors and pathways involved have not been clearly defined.

What the research shows on Thymogen

Most clinical reports are small and were published in Russian journals. In one, Thymogen was added to standard treatment in 46 women with acute or chronic inflammatory disease of the uterus and fallopian tubes. The authors reported normalization of lymphocyte counts, higher T- and B-cell numbers, better T-cell function, and no complications.⁷ The report does not describe a randomized control group, so the effect of Thymogen cannot be separated from the effect of the rest of the treatment or the natural course of the illness.

Reviews describe Thymogen as an interferon inducer used for decades in the former Soviet bloc for indications similar to those of interferons, such as viral infections.¹ That gives a picture of long clinical use, but long use is not the same as proven benefit. The underlying trials are rarely available in English, often lack placebo controls, and seldom report enough detail to judge their quality.

Laboratory work on the mirror-image pair Thymogen and Thymodepressin is more recent and of chemical interest, but it does not show clinical benefit in people.²

There are no large, randomized, blinded trials of Thymogen in any condition, and none in healthy people using it for prevention or longevity.

Studied for: Immune function research, Infection recovery research.

Thymogen reference data

Thymogen dosage in published research

Open this in the dosage calculator ↗

How Thymogen is used in practice

In Russia, Thymogen has been available as an injection and as a nasal spray. It is used in short courses, often 10 days or so, alongside standard treatment for infections, wound healing and states of weakened immunity. Bioregulator clinics sometimes recommend repeating courses several times a year.

In the US, it is not an approved drug. It is bought from online peptide vendors labeled for research use, or as imported product. Quality is unverified. A dipeptide is simple to make, but purity, sterility and accurate dosing still depend on the manufacturer. Doses and schedules circulating online are borrowed from Russian product information and bioregulator clinics rather than from dose-finding trials.

Some sellers list Glutoxim as a synonym for Thymogen. That is wrong. Glutoxim is a different Russian drug, from a class called thiopoietins, used mainly in tuberculosis.⁴ Research on Glutoxim does not apply to Thymogen.

Thymogen risks and side effects

Russian clinical reports describe Thymogen as well tolerated, and its chemistry, two common amino acids, is not inherently alarming. The most commonly reported effects are injection-site reactions and mild fatigue. However, safety monitoring in the published studies was limited, and rare or delayed effects would likely have been missed. The effects of repeating courses several times a year over many years have not been studied at all.

Because it is designed to stimulate immunity, caution is reasonable in people with autoimmune disease, organ transplants or treatment with immunosuppressive drugs. It has not been studied in pregnancy, and there is no meaningful data on use in people with active cancer. Drug interactions are essentially uncharacterized.

The largest practical risk for US buyers is the product itself: mislabeled or contaminated vials, nonsterile solutions and inaccurate doses from unregulated suppliers.

Reported side effects

Alternatives to Thymogen

For preventing infection, especially in older adults, vaccination has strong evidence: influenza, pneumococcal, shingles, RSV and COVID-19 vaccines where eligible. Sleep, physical activity, adequate protein and correction of zinc or vitamin D deficiency support immune function.

For diagnosed immune deficiencies, specialists use approved treatments such as immunoglobulin replacement. For active infections, antivirals and antibiotics matched to the cause remain the standard. Among thymic peptides, thymosin alpha-1 is better studied, with randomized trials in hepatitis and sepsis.

Questions for a clinician

• What evidence applies to my situation, and at what level?
• What established alternatives should I consider first?
• What monitoring would be necessary, and how often?
• Can this be prescribed at all where I live, or only sold for research?